application

Regeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License ApplicationRegeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License Application

Regeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License Application

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and…

2 weeks ago
DIAGNOS Provides Update on its Health Canada Medical Device Licence ApplicationDIAGNOS Provides Update on its Health Canada Medical Device Licence Application

DIAGNOS Provides Update on its Health Canada Medical Device Licence Application

BROSSARD, Quebec, April 09, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB:…

4 weeks ago
Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade OrderAvicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order

Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order

March 31, 2025 20:10 ET  | Source: Avicanna Inc. Auditor Licensing & Personnel Issues Delays Issuance of Audit OpinionThe Company…

1 month ago
KuCoin EU Files MiCAR Application in Austria to Ensure Compliant EEA OperationsKuCoin EU Files MiCAR Application in Austria to Ensure Compliant EEA Operations

KuCoin EU Files MiCAR Application in Austria to Ensure Compliant EEA Operations

Key Takeaways: KuCoin EU Exchange GmbH ("KuCoin EU") is applying for a Markets in Crypto-Assets Regulation ("MiCAR") license in Austria…

2 months ago
VCTI Launches BEAD Application Service to Help Broadband Providers Secure Funding Faster with Higher Business Case AccuracyVCTI Launches BEAD Application Service to Help Broadband Providers Secure Funding Faster with Higher Business Case Accuracy

VCTI Launches BEAD Application Service to Help Broadband Providers Secure Funding Faster with Higher Business Case Accuracy

BEAD Resource Center Launches on VCTI Website SOMERSET, N.J., Feb. 5, 2025 /PRNewswire/ -- VCTI, the broadband expansion and network…

3 months ago
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement…

3 months ago
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement…

3 months ago
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement…

3 months ago
Adam Ferrari Health Science Scholarship Application Window ClosesAdam Ferrari Health Science Scholarship Application Window Closes

Adam Ferrari Health Science Scholarship Application Window Closes

January 10, 2025 10:30 ET  | Source: The Ferrari Foundation DENVER, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The application period…

4 months ago
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastomaNorgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Back to media releasesNext media release LONDON, Jan. 7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing…

4 months ago